about
Emerging and future therapies for hemophiliaAntidrug Antibodies: B Cell Immunity Against TherapyNew treatments in hemophilia: insights for the clinician.International workshop on immune tolerance induction: consensus recommendations.Novel drugs to treat hemophilia.Joint protection in haemophilia.The modern treatment of haemophilia: a narrative reviewHaemophilia B: current pharmacotherapy and future directions.Alloantibodies in previously untreated hemophilia A patients: the role of environmental factors.Inhibitor eradication with rituximab in haemophilia: where do we stand?The role of Rixubis™ in the treatment of hemophilia B.Inhibitors in haemophilia A: a perspective on clotting factor products as a potential contributing factor.Physicians' preferences towards coagulation factor concentrates in the treatment of Haemophilia with inhibitors: a discrete choice experiment.Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better.Identification and characterization of an adenine to guanine transition within intron 10 of the factor VIII gene as a causative mutation in a patient with mild haemophilia A.Preclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia B.Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors.Continuous infusion in haemophilia: current practice in Europe.European principles of inhibitor management in patients with haemophilia.
P2860
Q26781143-CC9ABD20-F60C-47C6-92ED-7EC2E42F9699Q28082303-4F06C3E6-F139-417B-9DB4-976DA8FB898AQ36612681-99F898CD-7212-4B0B-A770-776025905159Q36861097-39A1CA50-6409-471D-84B7-B5CD3F7F5226Q37775029-69836366-0A2E-4382-93B2-BB5F61E0FB21Q37912258-D1807FA6-3543-415D-AE90-C549905F031FQ38025882-EAD6FDCE-0046-4535-879F-EADE0B1D1946Q38040458-178598FD-47C6-4B12-9338-80792EDC0F09Q38080144-28414EF5-B705-4C97-8E79-FF27AE0CB82EQ38195908-9BF2CF90-5BB2-46DA-9257-9451345AFBA8Q38210808-E2CB1898-48CD-4572-8386-C4B8143E05AAQ38722283-A7318292-EA25-48E2-9BB2-E89139E3B333Q39323587-4E54EE99-16E7-43BA-BCC4-C62EBE8855D1Q41917020-5C892F10-4B7E-4B21-B5C0-45300CF12EF5Q44846549-3410D077-74EF-43CB-9CB4-52BFE5794462Q45856730-A89BFCB5-0826-4A17-B6A8-F42A9B5972E8Q45868068-F4727586-AAF7-4DC0-98C3-09F973E99FA2Q45872851-DACA268B-B9CD-4FC0-BA4A-3E395356F5ABQ45878760-3DEA25F7-7BBD-4E2C-8AB6-547D72010180Q54981504-DE6428FA-34F2-4E8F-B809-DF3A35074EAF
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Overview of inhibitors.
@ast
Overview of inhibitors.
@en
type
label
Overview of inhibitors.
@ast
Overview of inhibitors.
@en
prefLabel
Overview of inhibitors.
@ast
Overview of inhibitors.
@en
P1476
Overview of inhibitors.
@en
P2093
Jan Astermark
P356
10.1053/J.SEMINHEMATOL.2006.03.006
P433
P577
2006-04-01T00:00:00Z